Cabazitaxel: A novel taxane for metastatic castration-resistant prostate cancer-current implications and future prospects

Recent advances in the management of prostate cancer have shown considerable development with time and many novel therapeutic agents have been approved over the past years. For patients with metastatic castration-resistant prostate cancer (mCRPC), initially docetaxel was the standard chemotherapy bu...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pharmacology & pharmacotherapeutics 2013-10, Vol.4 (4), p.230-237
Main Author: Abidi, Afroz
Format: Article
Language:English
Subjects:
Androgens
Cancer
Cancer therapies
Care and treatment
Drug dosages
Drug therapy
Health aspects
Marketing
Mini Review
Molecular weight
Mortality
Pharmacology
Population
Prostate cancer
Quality of life
Tumors
Vaccines
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recent advances in the management of prostate cancer have shown considerable development with time and many novel therapeutic agents have been approved over the past years. For patients with metastatic castration-resistant prostate cancer (mCRPC), initially docetaxel was the standard chemotherapy but once they became refractory to docetaxel, no treatment improved survival. This scenario changed in June 2010 when the US Food and Drug Administration (FDA) approved Cabazitaxel as a new therapeutic option for patients with mCRPC resistant to docetaxel. Cabazitaxel, being a novel tubulin-binding taxane with poor affinity for P-glycoprotein, decreases the chances of resistance. It has shown antitumor activity in preclinical, phase I, II and III clinical studies in docetaxel-resistant tumors. This article summarises the background, pharmacodynamic, kinetics and clinical development of cabazitaxel for the treatment of castration-resistant prostate cancer. Future development and rational use of this drug in other tumors is under therapeutic investigation.
ISSN:0976-500X
0976-5018
DOI:10.4103/0976-500X.119704